Table 1 Clinical characteristics of the retrospective cohort
NSCLC Patients | Melanoma | RCC | |||
|---|---|---|---|---|---|
Patients (n = 110) | All Case (n = 78) | Pre-ipi approval (n = 4) | Post-ipi approval (n = 74) | ICI Treated (n = 54) | |
Age at initial diagnosis (years) | |||||
< 30 | 1 (0.9%) | ||||
30–39 | 7 (9.0%) | 1 (25.0%) | 6 (8.1%) | 1 (1.9%) | |
40–49 | 3 (2.7%) | 14 (17.9%) | 1 (25.0%) | 13 (17.6%) | 6 (11.1%) |
50–59 | 26 (23.6%) | 13 (16.7%) | 1 (25.0%) | 12 (16.2%) | 21 (38.9%) |
60–69 | 41 (37.3%) | 19 (24.4%) | 1 (25.0%) | 18 (24.3%) | 16 (29.6%) |
70–79 | 30 (27.3%) | 18 (23.1%) | 18 (24.3%) | 10 (18.5%) | |
≥ 80 | 9 (8.2%) | 7 (9.0%) | 7 (9.5%) | ||
Mean | 65.4 | 60.6 | 48 | 61.3 | 59.5 |
Year of diagnosis (Range) | 2007–2017 | 1990–2016 | 2004–2009 | 1990–2016 | 1981–2016 |
Sex | |||||
Female | 58 (52.7%) | 26 (33.3%) | 2 (50.0%) | 24 (32.4%) | 14 (25.9%) |
Male | 52 (47.3%) | 52 (66.7%) | 2 (50.0%) | 50 (67.6%) | 40 (74.1%) |
Race | |||||
White | 91 (82.7%) | 78 (100.0%) | 4 (100.0%) | 74 (100.0%) | 41 (75.9%) |
Other | 14 (12.7%) | 7 (13.0%) | |||
Unknown | 5 (4.5%) | 6 (11.1%) | |||
Vital status at last follow up | |||||
Alive | 55.00 (50.0%) | 46.00 (59.0%) | 2.00 (50.0%) | 44.00 (59.5%) | 31.00 (57.4%) |
Dead | 55.00 (50.0%) | 32.00 (41.0%) | 2.00 (50.0%) | 30.00 (40.5%) | 23.00 (42.6%) |
Checkpoint inhibitor | |||||
atezolizumab | 2 (1.8%) | ||||
ipilimumab | 35 (44.9%) | 3 (75.0%) | 32 (43.2%) | ||
ipilimumab + nivolumab | 2 (1.8%) | 10 (12.8%) | 1 (25.0%) | 9 (12.2%) | |
nivolumab | 71 (64.5%) | 2 (2.6%) | 2 (2.7%) | 54 (100.0%) | |
pembrolizumab | 35 (31.8%) | 31 (39.7%) | 31 (41.9%) | ||
Months of follow up | |||||
< 1 | 48 (43.6%) | 21 (38.9%) | |||
3 | 6 (5.5%) | 1 (1.3%) | 1 (1.4%) | 1 (1.9%) | |
6 | 17 (15.5%) | 12 (15.4%) | 12 (16.2%) | 5 (9.3%) | |
10 | 22 (20.0%) | 15 (19.2%) | 15 (20.3%) | 14 (25.9%) | |
> 10 | 17 (15.5%) | 50 (64.1%) | 4 (100.0%) | 46 (62.2%) | 13 (24.1%) |
Median | 8 | 12.5 | 63 | 12 | 10 |